168 related articles for article (PubMed ID: 30825345)
1. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
[TBL] [Abstract][Full Text] [Related]
2. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
3. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
[TBL] [Abstract][Full Text] [Related]
5. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
Pu XY; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
[TBL] [Abstract][Full Text] [Related]
7. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
8. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
9. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
10. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
Tokunaga M; Yasuda M; Osamura RY; Itoh J; Mukai M; Shima M; Usui Y; Masuda A; Miyakita H; Terachi T
Oncol Rep; 2005 Jun; 13(6):1081-7. PubMed ID: 15870925
[TBL] [Abstract][Full Text] [Related]
11. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
del Vecchio MT; Tripodi SA; Arcuri F; Pergola L; Hako L; Vatti R; Cintorino M
Prostate; 2000 Sep; 45(1):51-7. PubMed ID: 10960842
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.
Wang X; Zhang J; Han B
Adv Anat Pathol; 2022 Jul; 29(4):252-258. PubMed ID: 35670702
[TBL] [Abstract][Full Text] [Related]
14. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
15. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Yamanaka K; Muramaki M; Kurahashi T; Gleave M; Hara I
Oncol Rep; 2005 Nov; 14(5):1371-5. PubMed ID: 16211311
[TBL] [Abstract][Full Text] [Related]
17. Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
Asai A; Miyata Y; Matsuo T; Shida Y; Hakariya T; Ohba K; Sakai H
Prostate; 2017 Feb; 77(3):255-262. PubMed ID: 27527525
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract][Full Text] [Related]
19. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
[TBL] [Abstract][Full Text] [Related]
20. PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
Erickson AM; Lokman U; Lahdensuo K; Tornberg S; Visapaa H; Bergroth R; Santti H; Petas A; Rannikko AS; Mirtti T
Prostate; 2020 Sep; 80(13):1118-1127. PubMed ID: 32634262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]